June 2025, Volume 2, No. 6
Table of Contents

Letter from the Editors

Need fresh inspiration for your medtech company as we navigate Q325? We’ve gathered insights from some of our LSI alumni thought leaders to help you stay ahead.

Select Medtech Industry Financings & Deals: May 2025, by Date Announced

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins—including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific—is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy.

Driven by the rise of robotic surgery and increased application across high-volume procedures, the global electrosurgical devices market is set to expand from ~$10.2 billion in 2024 to ~$14.7 billion by 2029. This Market Dive examines the driving forces behind this growth, competitive dynamics, and recent innovations that are reshaping the future of surgical energy.

Fueled by rising procedure volumes, steady demand for minimally invasive cardiovascular treatments, and global access expansion, the global interventional cardiology device market is projected to grow from $11.2 billion in 2024 to $14.1 billion by 2029. Despite persistent pricing pressures, innovation and procedural growth continue to push the market forward.

Every week, LSI’s Market Intelligence team tracks the shifts, signals, and standout stories shaping the global medtech landscape. From financial performance and product divestitures to shifting patient behavior and overlooked clinical needs, The Numbers newsletter offers a data-driven lens on what matters most. Here’s what the LSI Market Intelligence team tracked this past month across public company earnings, kidney health, sleep therapy, and diabetes devices.

South Korea Procedure Volumes: Stereotactic Radiosurgery Procedures, 2023-2030

This month, to accompany our Innovator Spotlight on Solenic Medical, we detail the latest LSI Market Intelligence data on the global, Asian, European, and U.S. forecast volume for knee replacement procedures.

Armed with a brain-computer interface built from a novel ultra-soft material and bolstered by FDA Breakthrough Device Designation, Axoft is taking on neurological disorders, starting with disorders of consciousness as its first clinical indication. With first-in-human cases now complete, CEO and Co-Founder Paul Le Floch shares how Fleuron, their proprietary implant material, is unlocking clinical potential—and a new frontier in neurotechnology.

James Lancaster of Solenic Medical is leading the charge against one of the most devastating complications in orthopedic surgery: periprosthetic joint infections (PJIs). Backed by FDA Breakthrough Device Designation, recent first-in-human clinical milestones, and a growing network of strategic partners, Solenic’s non-invasive platform harnesses alternating magnetic fields (AMFs) to eradicate biofilms on infected implants—without surgery. With early feasibility trials underway and expansion into global markets in motion, Lancaster is shaping a new frontier in infection control.

Celebrating the accomplishments of a few of the many bright stars in our LSI presenting company and speaker alumni community.

This month we’re showcasing technologies and organizations impacting our industry, and patient lives.

Trusted By The Companies Pioneering What’s Next

Work with us
Accelerate your business
We’re here to help you make smarter decisions and form stronger
partnerships through curated events, independent market intelligence
products and services, and digital-forward media.